Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · IEX Real-Time Price · USD
12.83
-1.04 (-7.50%)
At close: Jul 2, 2024, 4:00 PM
13.47
+0.64 (4.99%)
After-hours: Jul 2, 2024, 5:09 PM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 21.67, with a low estimate of 13 and a high estimate of 35. The average target predicts an increase of 68.90% from the current stock price of 12.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for STOK stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +71.47% | Jun 28, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +172.80% | May 7, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $21 → $20 | Strong Buy | Maintains | $21 → $20 | +55.88% | May 7, 2024 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +71.47% | May 6, 2024 |
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +71.47% | Apr 11, 2024 |
Financial Forecast
Revenue This Year
14.58M
from 8.78M
Increased by 66.03%
Revenue Next Year
17.54M
from 14.58M
Increased by 20.34%
EPS This Year
-2.33
from -2.38
EPS Next Year
-2.64
from -2.33
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 20.2M | 68.3M | 78.8M | 169.7M | 300.6M |
| Avg | 14.6M | 17.5M | 32.4M | 69.4M | 163.0M |
| Low | 4.1M | n/a | n/a | n/a | 9.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 129.6% | 368.2% | 348.9% | 423.2% | 333.1% |
| Avg | 66.0% | 20.3% | 85.0% | 113.9% | 134.9% |
| Low | -53.1% | - | - | - | -86.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.22 | -2.38 | -2.03 | 0.12 | 0.72 |
| Avg | -2.33 | -2.64 | -2.41 | -1.72 | -0.82 |
| Low | -2.46 | -3.36 | -2.56 | -2.88 | -2.37 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.